Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BioCentury is providing this content for free given the urgent need for information about the coronavirus crisis. Further analysis can be found in our COVID-19 Resource Center. For more, sign up for our daily email.
1012 Data Byte COVID vaccines
BioCentury & Infogram

Product Development

Data Bytes: COVID-19 vaccines by phase and modality

Oct 12, 2020 | 9:28 PM GMT

Among the 201 COVID-19 vaccines in development, at least 43 have reached the clinic.

Each vaccine modality comes with a different set of pros and cons and varying levels and durations of immunity.

Russia approved Sputnik V, a viral vector vaccine, in August based on Phase I/II immunogenicity data;  a group of international scientists has since identified issues with the reliability of the data.

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers